9th Circ. Won't Revive Investor Suit Over Hep B Drug Trials
A California federal judge was right to dismiss a proposed investor class action accusing Arrowhead Research Corp. of overstating clinical trial results for its hepatitis B medication, as the company didn't...To view the full article, register now.
Already a subscriber? Click here to view full article